			Minimum						Power Pulse®		Contrast		Maximum Run Times	11		
Model	Indication	Delivery Platform	Vessel Diameter	Catheter Length	Catheter Diameter	Guide Wire	Guide Catheter	Introducer Sheath	Delivery Enabled	Guidewire Swappable	Injection Port	Flow Rate	Total Run Time with Run Time Blood Flow	Order Information		
Distaflex®	Coronary Arteries & SVGs	0TW	2mm	145cm	4F/3F	0.014″	6F > .070"	4F (6F*)				23mL/min	600 sec 300 sec	111304-001 (Ultra)		
XMI®	Coronary Arteries, SVGs, & Peripheral Arterial	OTW	2mm	135cm	4F	0.014"	6F > .068"	4F (6F*)				40mL/min	600 sec 300 sec	105041-001 (Ultra)		
Spiroflex <sup>®</sup>	Coronary Arteries, SVGs, & Peripheral Arterial	RX	2mm	135cm	4F	0.014"	6F > .070"	5F (6F*)				40mL/min	600 sec 300 sec	106553-001 (Ultra)		
XVG®	Peripheral Arterial	0TW	3mm	140cm	5F	0.014"	7F > .076"	5F (6F*)				60mL/min	600 sec 300 sec	105042-001 (Ultra)		
Spiroflex <sup>®</sup> VG	Coronary Arteries, SVGs, & Peripheral Arterial	RX	3mm	135cm	5F	0.014"	7F > .076"	6F (7F*)				60mL/min	600 sec 300 sec	106608-001 (Ultra)		
Solent <sup>®</sup> Proxi	Peripheral Arterial and Venous, AV Access	0TW	3mm	90cm	6F	0.035"	-	6F	Yes	Yes	Yes	60mL/min	480 sec 240 sec	109676-001 (Ultra)		
Solent <sup>®</sup> Omni	Peripheral Arterial and Venous, AV Access	OTW	3mm	120cm	6F	0.035″	-	6F	Yes	Yes	Yes	60mL/min	480 sec 240 sec	109681-001 (Ultra)		
Solent <sup>®</sup> Dista	Peripheral Arterial	0TW	1.5mm	145cm	4F/3F	0.014"	-	4F	Yes			23mL/min	600 sec 300 sec	111303-001 (Ultra)		
AVX <sup>®</sup>	AV Access Grafts & Fistula	OTW	3mm	50cm	6F	0.035"	_	6F			Yes	60mL/min	600 sec 300 sec	105039-001 (Ultra)		
								Power Pulse Kit for Ultra 104834-002								
Aspiration Catheter <b>Fetch<sup>®</sup> 2</b>	Peripheral Arterial & Coronary Vasculature	RX	2mm	135cm	4F	0.014"	6F > .070"	5F	-	-	_	-		<b>109400-001</b> (Fetch <sup>®</sup> 2)		

\*When a guide catheter is utilized

## AngioJet<sup>®</sup> / Fetch<sup>®</sup> **Catheter Reference Guide**







## AngioJet<sup>®</sup> / Fetch<sup>®</sup> **Catheter Reference Guide**





# BAYER Bayer HealthCare

Manufacturer:

MEDRAD, INC. One Medrad Drive ndianola. PA 15051-0780 USA +1 (412) 767-2400 Other: +1 (800) 633-7231 Fax: +1 (412) 767-4120 www.medrad.com

European Authorized Representative:

MEDRAD Europe B.V. P.O. Box 205 6190 AE Beek The Netherlands Ph: +31 (0) 43-3585600

 $(E_{0086})$ 

4279-001 02/14

#### AngioJet<sup>®</sup> Ultra Thrombectomy System **Mechanism of Action**

1 The Angiolet Ultra Console monitors and controls the system.





Saline jets travel backwards to create a low pressure zone causing a vacuum effect.

Thrombus is drawn into the in-flow windows and the jets push the thrombus back down the catheter.



#### AngioJet<sup>®</sup> Thrombectomy Systems

General Indications/Contraindications - Angiolet System peripheral indications include: breaking up and removing thrombus from infra-inquinal peripheral arteries, upper and lower extremity peripheral arteries, upper extremity peripheral veins, ileofemoral, infra-iliac and lower extremity veins, A-V access conduits, and for use with the Angiolet Power Pulse Kit for the control and selective infusion of physician specified fluids, including thrombolytic agents, into the peripheral vascular system. AngioJet System coronary indications include: removing thrombus in the treatment of patients with symptomatic coronary artery or saphenous vein graft lesions prior to balloon angioplasty or stent placement. Do not use in patients: who are contraindicated for intracoronary or endovascular procedures, who cannot tolerate contrast media, and in whom the lesion cannot be accessed with the wire guide.

General Warnings and Precautions - The System has not been evaluated for treatment of pulmonary embolism in the US and some other countries or for use in the carotid or cerebral vasculature. Some AngioJet devices have not been evaluated for use in coronary vasculature. Operation of the catheter may cause embolization of some thrombus and/or thrombotic particulate debris. Cardiac arrhythmias may occur and cardiac rhythm should be monitored during catheter use and appropriate management employed, if needed. Systemic heparinization is advisable to avoid pericatheterization thrombus and acute rethrombosis. Operation of the System causes transient hemolysis. Large thrombus burdens may result in significant hemoglobinemia which should be monitored. Consider hydration, as appropriate. Before coronary Angiolet treatment, verify the presence of thrombus because routine use of AngioJet in every STEMI patient, without proper selection for thrombus, has been associated with increased mortality risk. Do not use the system in the coronary vasculature without placing a temporary pacing catheter to support the patient through hemodynamically significant arrhythmias which may occur.

Potential Adverse Events - Potential adverse events (in alphabetical order) which may be associated with use of the system are similar to those associated with other interventional procedures and include but are not limited to the following: abrupt closure of treated vessel, acute myocardial infarction, acute renal failure, arrhythmias (including VF and VT), bleeding from access site, death, dissection, embolization (proximal or distal), emergent CABG, hematoma, hemolysis, hemorrhage requiring transfusion, hypotension/hypertension, infection at access site, myocardial ischemia, pain, pancreatitis, perforation, pseudoaneurysm, reactions to contrast medium, stroke/CVA, thrombosis/occlusion, total occlusion of treated vessel, vascular aneurysm, vascular spasm, vessel wall or valve damage.

Indications, operating specifications and availability may vary by country. Check with local product representation and country-specific Information For Use for your country.

CAUTION: Federal (USA) Law restricts the device to sale by or on the order of a physician.

Bayer, the Bayer Cross, MEDRAD, Angiolet, AVX, Fetch, Power Pulse, Solent, Spiroflex, XMI and XVG are trademarks of Bayer group of companies. Bayer © 2014